Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DC9FD4
|
|||
| Drug Name |
RC-01
|
|||
| Indication | Gram-negative bacterial infection [ICD-11: 1B74-1G40] | Terminated | [1] | |
| Company |
Recida Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Lipopolysaccharide biosynthesis | |||
| Metabolic pathways | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The global preclinical antibacterial pipeline. Nat Rev Microbiol. 2020 May;18(5):275-285. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.